# A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

> **NCT03546894** · — · COMPLETED · sponsor: **Takeda** · enrollment: 111 (actual)

## Conditions studied

- Anaplastic Lymphoma Kinase-positive
- Carcinoma Non-small-cell Lung

## Interventions

- **DRUG:** Brigatinib
- **DRUG:** Alectinib
- **DRUG:** Ceritinib
- **DRUG:** Lorlatinib
- **DRUG:** Any FDA Approved ALK Inhibitors

## Key facts

- **NCT ID:** NCT03546894
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-23
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-02-13
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546894, "A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03546894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*